Reliance on third-party software vendors differentiates INC Research from its technology-investing peers but will not be a disadvantage, according to a Jefferies analyst.
New research suggests that – in general - strategic partnerships are working but CROs still need to improve on sponsors’ ‘high priority’ objectives or risk losing deals.
Charles River Laboratories’ (CRL) preclinical division will continue to struggle in 2012 but the recent uptick in strategic partnership activity is a ray of hope according to a leading analyst.
The first wave of strategic deals is coming up for renewal, allowing sponsors to pressure pricing by tweaking contracts or, in extreme cases, switch partners.
